Ovid Therapeutics develops targeted small molecule therapies aimed at reducing seizures in patients with epilepsy and other neurological conditions. Their approach focuses on unique mechanisms of action to enhance safety and tolerability, ultimately improving the quality of life for affected individuals and families.
Funding
Funding not disclosed
Founders
Product
Problem
Many individuals with epilepsy and other neurological conditions experience frequent seizures, which can significantly impair their quality of life. Current treatments may have limited efficacy or be associated with undesirable side effects, highlighting the need for more targeted and tolerable therapies.
Solution
Ovid Therapeutics is developing a new generation of targeted small molecule therapies designed to reduce seizures in patients with epilepsy and other neurological conditions. Their approach focuses on identifying compounds with unique or potential best-in-class mechanisms of action to enhance safety and tolerability. By pioneering effective new treatments, Ovid Therapeutics aims to improve the lives of individuals and families affected by neurological diseases and potentially change the course of disease.
Target Audience
The primary target audience includes individuals with epilepsy and other neurological conditions, as well as their families and caregivers.
Features
- Development of small molecule therapies targeting neurological conditions.
- Focus on unique mechanisms of action for improved efficacy.
- Emphasis on enhancing safety and tolerability profiles.
- Pipeline includes programs such as OV329, OV350 & KCC2 Library, OV888/GV101 Capsule, and Soticlestat.